SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-090145
Filing Date
2024-08-02
Accepted
2024-08-02 17:26:54
Documents
14
Period of Report
2024-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240802.htm   iXBRL 8-K 49232
2 EX-1.1 awh-ex1_1.htm EX-1.1 384199
3 EX-5.1 awh-ex5_1.htm EX-5.1 31707
4 GRAPHIC img170348524_0.jpg GRAPHIC 14741
  Complete submission text file 0000950170-24-090145.txt   666526

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT awh-20240802.xsd EX-101.SCH 25815
16 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240802_htm.xml XML 4896
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241172381
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)